Skip to main content

Axatilimab ± Azacitidine

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

  • RegistryNCT06523556
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionAdvanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMML
  • SponsorUma Borate
How Axatilimab worksNCT065235561 min

What the film says

Read the transcript

This trial is for adults with advanced myeloproliferative neoplasms, overlap syndromes with myelodysplastic syndrome, or high risk chronic myelomonocytic leukemia.

The idea: give axatilimab, an antibody given by vein that blocks a protein on certain white blood cells that may help the cancer grow. The first part tests axatilimab alone. The second part adds azacitidine, a standard chemotherapy.

The study looks for the best dose and how well it works.

This phase 1 and 2 study plans 49 patients. At Ohio State University Comprehensive Cancer Center in Columbus, Uma Borate leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06523556

    Adults; advanced MPN, MPN/MDS overlap, high-risk CMML; Axatilimab antibody IV blocks protein on white blood cells; Phase I alone; phase II adds azacitidine; Best dose and effectiveness (+1 more lines)

The drug

What is being tested.

PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of axatilimab in relapsed or refractory patients with advanced phase MPN, MPN/MDS overlap or high-risk CMML. II. To evaluate the overall response rate of axatilimab + azacitidine (AZA) in newly diagnosed patients with advanced phase MPN, MPN/MDS overlap or high-risk CMML using Savona response criteria. SECONDARY OBJECTIVES: I.

Determine the safety and tolerability of axatilimab + azacitidine combination therapy in those with newly diagnosed advanced phase MPN, MPN/MDS overlap or high-risk CMML. II. Determine the quality of life in patients receiving axatilimab + AZA using a Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF). III.

Giving axatilimab with or without azacitidine may be safe and effective in treating patients with advanced phase MPN, MPN/MDS overlap or high risk CMML.

The study

How the trial runs.

This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS) overlap or high risk chronic myelomonocytic leukemia (CMML).

Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, this may slow or halt the growth of the cancer. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Signed informed consent must be obtained prior to participation in the study
  • Age ≥ 18 years at the date of signing the informed consent form (ICF)
  • Chronic myelomonocytic leukemia (CMML), classified as intermediate-2, OR high-risk per the CMML Specific Prognostic Scoring System (CPSS) Molecular Model
  • Atypical chronic myelocytic leukemia (aCML)
  • MDS/MPN unclassified (MDS/MPN-U)

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.